Cross - validation | Src inhibitors | Src non-inhibitors | Q | C | ||||||
---|---|---|---|---|---|---|---|---|---|---|
No of training/ testing inhibitors | TP | FN | SE | No of training/testing non-inhibitors | TN | FP | SP | |||
1 | 1362/341 | 320 | 21 | 93.84% | 50654/12664 | 12651 | 13 | 99.90% | 99.74% | 0.948 |
2 | 1362/341 | 324 | 17 | 95.01% | 50654/12664 | 12650 | 14 | 99.89% | 99.76% | 0.953 |
3 | 1362/341 | 324 | 17 | 95.01% | 50654/12664 | 12640 | 24 | 99.81% | 99.68% | 0.939 |
4 | 1363/340 | 318 | 22 | 93.53% | 50655/12663 | 12642 | 21 | 99.83% | 99.67% | 0.935 |
5 | 1363/340 | 322 | 18 | 94.71% | 50655/12663 | 12643 | 20 | 99.84% | 99.71% | 0.943 |
Average | Â | Â | Â | 94.42% | Â | Â | Â | 99.85% | 99.71% | 0.944 |
SD | Â | Â | Â | 0.0069 | Â | Â | Â | 0.0004 | 0.0004 | 0.0072 |
SE | Â | Â | Â | 0.0031 | Â | Â | Â | 0.0002 | 0.0002 | 0.0032 |